8-K Announcements
6Material company update
May 28, 2026·SEC
Material company update
Apr 21, 2026·SEC
Material company update
Mar 31, 2026·SEC
ENDRA Life Sciences Inc.(NDRA)Earnings, Financials & Key Ratios
NDRA•NASDAQ
$4.99
Price updated Jun 27, 2026
AboutENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.Show more
- Revenue$0
- EBITDA-$6M+47.2%
- Net Income-$7M+38.9%
- EPS (Diluted)-8.93+12.9%
- ROE-291.56%-4.1%
NDRA Price & Volume
ENDRA Life Sciences Inc. (NDRA) stock price & volume — 10-year historical chart
Loading chart...
Persistent Pre-Revenue Status Threatens Operational Continuity
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
"ENDRA Life Sciences faces a critical juncture as its TAEUS platform remains pre-revenue after ten quarters, leaving the firm entirely dependent on external financing to cover persistent operating losses. The company's financial health is severely compromised by a shrinking asset base and a current ratio of 0.64, which suggests an imminent risk of insolvency. Investors should monitor the firm's ability to secure non-dilutive capital, as the current burn rate and $111.8 million in accumulated losses present a significant barrier to long-term shareholder value creation."
Verdict Logic
the company's current ratio of 0.64 and the depletion of cash to $356,500 indicate a high probability of further dilutive financing or potential going concern risks.
NDRA Growth Metrics
ENDRA Life Sciences Inc. (NDRA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM25.24%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM37.23%
Return on Capital
10 Years-342.96%
5 Years-161.05%
3 Years-181.9%
Last Year-165.85%
NDRA Recent Earnings
ENDRA Life Sciences Inc. (NDRA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q2 2026Latest
May 18, 2026Metric
Actual
Est
EPS
$1.09+11.4%
$1.23
Rev
—
—
Q2 2026
May 15, 2026Metric
Actual
Est
EPS
$1.09+11.4%
$1.23
Rev
—
—
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$3.26-165.0%
$1.23
Rev
—
$100,000
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$1.75+10.3%
$1.95
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 18, 2026 | $1.09vs $1.23+11.4% | — |
| Q2 2026 | May 15, 2026 | $1.09vs $1.23+11.4% | — |
| Q2 2026 | Mar 31, 2026 | $3.26vs $1.23-165.0% | —vs $100,000 |
| Q4 2025 | Nov 14, 2025 | $1.75vs $1.95+10.3% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for ENDRA Life Sciences Inc. (NDRA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.99 | $3.76M | -0.56 | — | — | -291.56% | — | |
| $5.72 | $239.06M | -3.45 | 56.89% | -214.16% | -130% | — | |
| $109.80 | $7.15B | 32.20 | 0.5% | 18.05% | 24.33% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $5.59 | $69.84M | -22.36 | 14.52% | -9.05% | -70.95% | — | |
| $18.48 | $554.21M | -20.53 | 17.78% | -71.57% | -140.96% | — |
Compare NDRA vs Peers
ENDRA Life Sciences Inc. (NDRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NDRA SEC Filings & Documents
ENDRA Life Sciences Inc. (NDRA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when NDRA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NDRA Frequently Asked Questions
ENDRA Life Sciences Inc. (NDRA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is NDRA profitable?
ENDRA Life Sciences Inc. (NDRA) reported a net loss of $7.3M for fiscal year 2025.
Dividend & Returns
What is NDRA's return on equity?
ENDRA Life Sciences Inc. (NDRA) has a return on equity (ROE) of -291.6%. Negative ROE indicates the company is unprofitable.
What is ENDRA Life Sciences Inc.'s free cash flow?
ENDRA Life Sciences Inc. (NDRA) had negative free cash flow of $8.0M in fiscal year 2025, likely due to heavy capital investments.